Her2 low status and response to neoadjuvant chemotherapy in Her2 negative early breast cancer

被引：0
|
作者：
Mattos, Bruna RaphaeliSilva [1 ]
Cesca, Marcelle Goldner [1 ]
Leite, Luciana de Moura [1 ]
Tavares, Monique Celeste [1 ]
Silva, Sinara Figueiredo [1 ]
Pirolli, Rafaela [1 ]
Fogassa, Camilla AlbinaZanco [1 ]
Silva, Erick Figueiredo [1 ]
Rocha, Francisca Giselle [1 ]
Loose, Simone Klug [1 ]
Campos, Fernando AugustoBatista [1 ]
Sanches, Solange Moraes [1 ]
de Lima, Vladmir ClaudioCordeiro [1 ]
Ponde, Noam Falbel [1 ]
机构：
[1] AC Camargo Canc Ctr, Sao Paulo, Brazil
来源：
CANCER RESEARCH | 2021年 / 81卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PS4-40
引用
收藏
页数：2
相关论文
共 50 条
  • [21] HER2 Expression in Triple-Negative Breast Cancer: Clinicopathologic Features and Response to Neoadjuvant Chemotherapy
    Morante, Zaida
    Otoya, Iris
    Valdivieso, Natalia
    Calle, Cindy
    Fuentes, Hugo
    Neciosup, Silvia
    Castaneda, Carlos
    Vidaurre, Tatiana
    Falla, Martin
    Colomo, Valeria
    Gomez, Henry
    [J]. CANCER RESEARCH, 2024, 84 (09)
  • [22] Predictors of Response to Standard Neoadjuvant Chemotherapy in Estrogen Receptor Positive, HER2 Negative Breast Cancer
    Bhargava, R.
    [J]. MODERN PATHOLOGY, 2012, 25 : 26A - 26A
  • [23] Evaluating the efficacy of neoadjuvant endocrine therapy in HER2 low vs. HER2 negative breast cancer: An NCBD analysis
    Chong, Esther G.
    Guo, Mengni
    Castillo, Dani Ran
    Bazan, Jose G.
    Yap, Kelly Khai Li
    Schultz-Costello, Katharine
    Wu, S. Peter
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    [J]. MODERN PATHOLOGY, 2019, 32
  • [25] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Meisel, Jane
    Suo, Aili
    Zhang, Chao
    Wei, Zhimin
    Aneja, Ritu
    Li, Zaibo
    Nahta, Rita
    Li, Xiaoxian
    [J]. MODERN PATHOLOGY, 2019, 32
  • [26] Discordance in hormone receptor and HER2 status in breast cancer during neoadjuvant chemotherapy
    Maeda, S.
    Tohyama, H.
    Tokai, H.
    Kamohara, Y.
    Nagata, Y.
    Fujioka, H.
    Itoh, M.
    [J]. BREAST, 2011, 20 : S73 - S73
  • [27] Changes in Hormone Receptor and Her2 Status After Neoadjuvant Chemotherapy in Breast Cancer
    Kaya, Ali Osman
    Buyukberber, Suleyman
    Yamac, Deniz
    Coskun, Ugur
    Yildiz, Ramazan
    Yaman, Emel
    Ozturk, Banu
    Benekli, Mustafa
    [J]. TURKIYE KLINIKLERI TIP BILIMLERI DERGISI, 2010, 30 (02): : 469 - 473
  • [28] Evaluating Low HER2 Status in Breast Cancer Cases with Absent and Low HER2 Protein Expression
    Ardor, Gokce
    Komforti, Miglena
    Hanna, Helena
    Nassar, Aziza
    [J]. LABORATORY INVESTIGATION, 2023, 103 (03) : S94 - S95
  • [29] HER2 Immunohistochemistry Positivity is Strongly Predictive of HER2 Positive Breast Cancer Response to Neoadjuvant Therapy
    Zhao, Jing
    Zhang, Chao
    Suo, Aili
    Shi, Qiuying
    Wei, Zhimin
    Li, Zaibo
    Krishnamurti, Uma
    Li, Xiaoxian
    [J]. LABORATORY INVESTIGATION, 2019, 99
  • [30] Hormone receptor and HER2 status: The only predictive factors of response to neoadjuvant chemotherapy in breast cancer
    Baulies, S.
    Cusido, M.
    Gonzalez-Cao, M.
    Tresserra, F.
    Fargas, F.
    Rodriguez, I.
    Ubeda, B.
    Ara, C.
    Fabregas, R.
    [J]. JOURNAL OF OBSTETRICS AND GYNAECOLOGY, 2015, 35 (05) : 485 - 489
12345